	US 12,441,986 B2
	Methods and compositions for the clinical derivation of a stem cell and therapeutic uses
Amit Patel, Miami, FL (US)
Assigned to Jadi Cell LLC, Miami, FL (US)
Filed by Jadi Cell LLC, Willmington, DE (US)
Filed on Dec. 22, 2021, as Appl. No. 17/559,583.
Application 17/559,583 is a continuation of application No. 17/322,672, filed on May 17, 2021, abandoned.
Application 17/322,672 is a continuation of application No. 15/799,743, filed on Oct. 31, 2017, abandoned.
Application 15/799,743 is a continuation of application No. 13/732,204, filed on Dec. 31, 2012, granted, now 9,803,176, issued on Oct. 31, 2017.
Claims priority of provisional application 61/591,211, filed on Jan. 26, 2012.
Claims priority of provisional application 61/582,070, filed on Dec. 30, 2011.
Prior Publication US 2022/0251515 A1, Aug. 11, 2022
Int. Cl. C12N 5/073 (2010.01); A61K 35/51 (2015.01); C12N 5/071 (2010.01); C12N 5/077 (2010.01)

CPC C12N 5/0682 (2013.01) [A61K 35/51 (2013.01); C12N 5/0605 (2013.01); C12N 5/0653 (2013.01); C12N 5/0654 (2013.01); C12N 5/0655 (2013.01); C12N 5/0657 (2013.01)]

8 Claims

1. A method of making a plurality of isolated cells capable of self-renewal and culture expansion, comprising:

extracting isolated cells from a subepithelial layer of a mammalian umbilical cord being capable of self-renewal and culture expansion, further comprising;

removing Wharton's Jelly to expose the subepithelial layer of the mammalian umbilical cord; and

placing the subepithelial layer in contact with a growth substrate; and

and culturing the isolated cells in a culture medium to create the culture of isolated cells,

wherein the isolated cells express at least three cell markers selected from the group consisting of CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and

wherein the isolated cells do not express NANOG and do not express CD106, Stro-1, and CD117.